Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate (PALANGI3)

March 12, 2026 updated by: Centre Oscar Lambret

Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study)

The purpose of this study is to determine the maximum tolerated dose of imatinib mesylate, given in association with a fixed dose of cyclophosphamide (50 mg bid).

Study Overview

Status

Completed

Conditions

Cancer

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

Phase

Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

France
- - Bordeaux, France, 33076
    - Institut Bergonie
  - Lille, France, 59020
    - Centre Oscar Lambret
  - Lyon, France, 69008
    - Centre Léon Bérard

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Rare tumor
metastatic disease or locally advanced disease, inoperable, with no standard treatment
At least 28 days since the prior treatment
Measurable disease with at least one measurable lesion

Exclusion Criteria:

Medullary insufficiency
Cystitis, haemorrhagic cystitis
Hepatic porphyria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: N/A
Interventional Model: Single Group Assignment
Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
For safety: NCI-CTCAE scale version 3.0 Time Frame: 42 days	42 days

Secondary Outcome Measures

Outcome Measure	Time Frame
For anti tumoral efficiency : RECIST criteria Time Frame: 70 days	70 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Oscar Lambret

Investigators

Principal Investigator: Antoine ADENIS, MD, PhD, Centre Oscar Lambret

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 9, 2009

Primary Completion (Actual)

April 1, 2011

Study Completion (Actual)

February 1, 2012

Study Registration Dates

First Submitted

January 11, 2010

First Submitted That Met QC Criteria